Compare CDMOs with immunology drug manufacturing expertise for monoclonal antibodies, bispecifics, cell therapies, and immunomodulators. Filter by modality, scale, and regulatory approvals.
133 companies listed
Immunology manufacturing is at the intersection of the largest biologic drug classes. Monoclonal antibodies targeting immune pathways (anti-TNF, anti-IL-6, anti-PD-1/PD-L1) account for the majority of biologic drug revenue globally. The field continues to expand with bispecific antibodies, ADCs, CAR-T cell therapies, and next-generation immunomodulators that require increasingly specialized manufacturing capabilities.
Bispecific antibodies are the next manufacturing challenge. Unlike standard monoclonal antibodies, bispecifics (targeting two different antigens simultaneously) require novel production strategies: knobs-into-holes, CrossMab, common light chain, or tandem scFv formats. Each format has different upstream and downstream manufacturing requirements. CDMOs with experience across multiple bispecific platforms provide strategic flexibility for sponsors developing these next-generation immunotherapies.
Cell therapy manufacturing for immunological applications extends beyond oncology. CAR-T and TCR-T therapies are being developed for autoimmune diseases (lupus, multiple sclerosis), transplant rejection, and chronic infections. Manufacturing requirements are similar to oncology cell therapies -- GMP-grade viral vectors, cell processing in classified environments, cryopreservation, and patient-specific supply chain logistics -- but the scale and disease-specific modifications may differ.
United States
DUPLICATE ENTRY -- This is the same company as 'Pace Analytical Services LLC (Pace Life Sciences)' (company index 10). Pace Life Sciences is the CDMO/CRO division of Pace Analytical. Same website content, same capabilities. See company index 10 for full profile.
United States
Padagis LLC is a U.S.-based generic pharmaceutical company specializing in development and manufacturing of extended topical and specialty pharmaceutical products. Product portfolio includes prescription creams, ointments, gels, foams, sprays, patches, nasal treatments, and suppositories, with a focus on Paragraph IV generic products. Also manufactures naloxone nasal spray (awarded New York State Department of Health contract in 2025). Over 1,300 employees. Offers contract manufacturing, licensing, and joint venture partnerships.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.